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Abstract
Despite genetics being accepted as the primary cause of familial aggregation for most dis-
eases, it is still unclear whether afflicted families are likely to share a single highly penetrant
rare variant, many minimally penetrant common variants, or a combination of the two types
of variants. We therefore use recent estimates of SNP heritability and the liability threshold
model to estimate the proportion of afflicted families likely to carry a rare, causal variant. We
then show that Polygenic Risk Scores (PRS) may be useful for identifying families likely to
carry such a rare variant and therefore for prioritizing families to include in sequencing stud-
ies with that aim. Specifically, we introduce a new statistic that estimates the proportion of
individuals carrying causal rare variants based on the family structure, disease pattern, and
PRS of genotyped individuals. Finally, we consider data from the MelaNostrum consortium
and show that, despite an estimated PRS heritability of only 0.05 for melanoma, families car-
rying putative causal variants had a statistically significantly lower PRS, supporting the idea
that PRS prioritization may be a useful future tool. However, it will be important to evaluate
whether the presence of rare mendelian variants are generally associated with the proposed
test statistic or lower PRS in future and larger studies.
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Author summary
Multiple members in a family can be diagnosed with the same disease. In such families,
genetics may be a significant factor in disease risk. However, it remains unclear whether
such familial aggregation of disease is likely due to a single highly penetrant rare variant
(HPRV), many minimally penetrant common variants, or a combination of the two types
of variants. We therefore use recent estimates of SNP heritability and the liability thresh-
old model to estimate the proportion of afflicted families likely to carry a rare, causal vari-
ant. We then show that Polygenic Risk Scores (PRS) may be useful for identifying families
likely to carry such a rare variant and introduce a related statistic that can be used to select
families for sequencing studies trying to identify HPRV.
Introduction
Genetics is the primary cause for familial aggregation of disease [1]. In afflicted families, mem-
bers often share either a single highly penetrant rare genetic variant (HPRV) [2], a large num-
ber of minimally penetrant common variants [3], or both[4]. In this article we have two
objectives. First, we show that a non-negligible fraction of familial aggregation may be attribut-
able to common variants. Second, given this fact, we show that sequencing studies should try
to select families with members having low Polygenic Risk Scores (PRS) (i.e. few risk alleles at
common variants) when the study’s objective is to identify new highly penetrant rare variants.
Importantly, the genotyping needed for calculating PRS is usually inexpensive relative to full
sequencing.
The importance of common variation in the familial aggregation of disease is demonstrated
by the large estimates of SNP heritability [5] and the elevated PRS in members of afflicted fam-
ilies. High PRS has already been reported for families with migraines [6], dyslipidemia [7, 8],
Crohn’s disease [9], Alzheimer’s [10], schizophrenia [11], and breast cancer with [12] and
without [13–15] BRCA mutations. The increased number of common risk variants can either
be solely responsible for the familial aggregation of disease or can exaggerate [16] the pene-
trance of an HPRV. In the first half of this paper, we suggest that for many diseases with high
SNP heritability and a prevalence above 1%, a non-negligible proportion of afflicted families
may not harbor an HPRV.
As only a fraction of afflicted families will have an HPRV, sequencing studies intended to
identify new HPRV should preferentially select those families most likely to carry such a vari-
ant. For our discussion, we consider a sequencing study that compares the proportion of indi-
viduals in the selected families with a specific HPRV with the proportion of individuals in a
large, biobank-sized, set of controls carrying that HPRV. Therefore, the power for this illustra-
tive study, as well for many other types of sequencing studies, will be determined by the pro-
portion of tested family members with the HPRV. As initially discussed in Jostins [17], such
preferential selection can be achieved by selecting families with the lowest PRS. Therefore, in
the second half of this paper, we define a PRS-based statistic for prioritizing families and
explore the potential for preferential selection to increase the statistical power of the illustrative
study. We acknowledge that prioritization may only be useful in the near future, while the gen-
otyping needed to obtain the PRS is actionably less expensive than sequencing or we continue
to work with families that have already been genotyped. Furthermore, we use results from a
recent Whole-Exome-Sequencing (WES) Study of Melanoma Families from the MelaNostrum
consortium to provide an example where families with putative HPRV appear to have lower
PRS than other afflicted families.
Common Genetic Variants and Familial Aggregation
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008490 November 15, 2019 2 / 15
2014_SGR_603 and 2017_SGR_1134 of the
Catalan Government, Spain; by a grant from
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Our article proceeds as follows. In the results section, we describe HPRV prevalence in
afflicted families, demonstrate the potential for PRS-guided selection to increase study power,
and discuss the relationship between PRS and the presence of HPRV in the MelaNostrum con-
sortium. In the discussion section, we review the key points, relate our approach to the litera-
ture, and suggest next steps. In the methods section, we summarize notation, define our PRS
statistic, provide full details on the scenarios used for evaluating familial aggregation, and
describe the MelaNostrum consortium. Finally, it is important to note that this article, with its
theory grounded in a simple liability threshold model, is intended to provide only rough
approximations of HPRV prevalence and study power. However, despite the dependence on
this model, we believe that our conclusions, at least qualitatively if not quantitively, are valid.
Results
We start by describing how the specific features of a disease affect the proportion of affected
family members expected to carry an HPRV and the ability of our proposed PRS-based statistic
to identify those families with members carrying an HPRV. Specifically, we consider these
relationships in affected sibships (e.g. bottom level of Fig 1A) and multi-generational families
(e.g. bottom two levels of Fig 1B). We explore the relationships using the simulations described
in the Methods section and, for reference, we note that the notation used to describe the evalu-
ated features are fully listed in the Methods: Notation section.
The first result is that the proportion of affected family members carrying an HPRV
depends on the genetic architecture of the disease. The proportion (Ep) carrying an HPRV
increases with increasing HPRV MAF (pG), penetrance in individuals carrying a single HPRV
(π1), and disease frequency in the family; and the proportion decreases with increasing disease
prevalence (π
�
) and polygenic heritability (s2P). We note, at this time, the polygenic heritability
is usually an order of magnitude higher than the PRS heritability (s2S). Figs 2 and S2 show
examples for affected sibships and Figs 3 and S3 show examples for multi-generational fami-
lies. For example, consider diseases that have a prevalence of π� = 0.02 and a heritability of
Fig 1. Examples family structure. (A) This example of the two-generation family structure has a founding couple with nD
1
¼ 4 affected children and nT
1
¼ 4 total
children. (B) This example of the three-generation family structure has a founding couple with nD
1
¼ 2 affected children, nT
1





¼ 9 total grandchildren.
https://doi.org/10.1371/journal.pgen.1008490.g001
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s2P ¼ 0:3 (e.g. [5] ischemic stroke, Barret’s esophagus, schizophrenia). In sibships where all
four siblings develop disease, approximately 5%, 30%, and 80% of the affected siblings will
have an HPRV if the total MAF of HPRVs is 0.00001, 0.0001, and 0.001 (Fig 2B) in our evalu-





with nTg being the number of biologically related individuals in the g
th generation) where 6 of
the 12 relevant individuals have disease, approximately 10%, 60%, and 90% of cases carry an
HPRV when the MAF is 0.00001, 0.001, and 0.001 (Fig 3B). Note, percentages decrease dra-
matically when the prevalence increases to 5% (S2 and S3 Figs).
The second result is that families with larger values of our newly proposed test statistic, Ti,
will be more likely to include individuals with an HPRV. Although the formal definition is
postponed until the Methods, Ti reflects the expected number of HPRV per affected individual
Fig 2. Proportion carrying HPRV in affected sibships. The proportion (Ep) of individuals carrying a highly penetrant rare variant (HPRV) in affected sibships for
a disease with a 2% prevalence (100 × π�) in the population. Panels A, B, and C represent different values of polygenic heritability (A: s2P ¼ 0:15, B: s2P ¼ 0:30, C:
s2P ¼ 0:45). Within a panel, the four sets of bars represent different MAF (pG = 0.00001, 0.0001, 0.001, or 0.01; note, the number in parenthesis is the resulting













Supporting Information: S2 Fig for diseases with other prevalences.
https://doi.org/10.1371/journal.pgen.1008490.g002
Fig 3. Proportion carrying HPRV in multi-generational families. The proportion (Ep) of individuals carrying a highly penetrant rare variant (HPRV) in affected
multi-generational families for a disease with a 2% prevalence (100×π�) in the population. Panels A, B, and C represent different values of polygenic heritability (A:
s2P ¼ 0:15, B: s
2
P ¼ 0:30, C: s
2
P ¼ 0:45). Within a panel, the four sets of bars represent different MAF (pG = 0.00001, 0.0001, 0.001, or 0.01; note, the number in













¼ 9). See Supporting Information: S3 Fig for diseases with other prevalences.
https://doi.org/10.1371/journal.pgen.1008490.g003
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in a given family based on the pattern of disease and polygenic risk scores (PRS). We note that
although Ti can be used to rank families, the ability of that ranking to differentiate families
with and without an HPRV strongly depends on both the genetic architecture and predictive
accuracy of the PRS. As an example, we describe HPRV enrichment in diseases that have a
total polygenic heritability of s2P ¼ 0:3, a prevalence of π
� = 0.02, and an HPRV MAF of pG =
0.0001 (Fig 4). Here, enrichment, M, is defined as a ratio, where we divide the average number
of HPRV in afflicted families at a given value of Ti by the average number of HPRV in all
afflicted families. For an affected sibship with four cases, families with Ti at the top 20th percen-
tile have a 2.5-fold enrichment in HPRV, as compared to the average affected sibship, when
the PRS heritability is high (s2S ¼ s
2
P ¼ 0:3) and a 1.5-fold enrichment when the PRS heritabil-
ity is more modest (s2S ¼ 0:05). Here, s
2
S denotes the polygenic heritability captured by the
PRS. For the multi-generational family with six cases, families with Ti at the top 20th percentile
have a 1.8-fold enrichment and a 1.4-enrichment in HPRV when the PRS heritability is 0.3
and 0.05 respectively. We note that relatively high enrichment for HPRV even when the s2S is
small is consistent with the behavior of the liability threshold model (see S1 Fig) which ensures
individuals with low PRS are unlikely to have the disease.
The next result is that studies which preferentially select families with higher values of our
proposed statistic can have increased power to detect associated HPRV. Details of the assumed
study design and statistical test are presented in the Methods Section Briefly, we first assume
that we select a group of families with a specific family structure for the sequencing study.
Then, we compare the proportion of afflicted family members carrying a specific HPRV to the
proportion of a large set of unaffected controls carrying that HPRV. Again, we consider the
ideal example with s2P ¼ 0:3, π
� = 0.02, and pG = 0.0001 (Fig 4). Note, for the discussed fami-
lies, these parameters are ideal because about 50% of the families carry an HPRV and therefore
intelligent selection can be beneficial. For an affected sibship with four cases or the multi-gen-
erational family with 6 cases, a study that selects families with Ti in the top 20th percentile has
notably higher power to detect a statistically significant association than a study that randomly
selects the same number of families, even when the PRS heritability is modest (s2S ¼ 0:05).
Note, if using all families results in a power of approximately 0.5, it is expected that a study
using only a randomly selected 20% of the families yields a power near 0. However, a study
that enriches the HPRV in that 20% of subjects by a factor of 1.5–2.0x (i.e. selects families
Fig 4. Enrichment and power to detect HPRV by the PRS statistic. Panels A and B show the enrichment (M) of HPRV as a function of the PRS statistic for a sibship
with four affected individuals and a multi-generational family with six affected individuals. The X-axis is the quantile of the statistic (i.e. 0.1 represents a family at the
top 10th percentile). Panels C and D show the power (β) to detect an association with the HPRV when a sibship has four affected individuals and when a multi-
generational family has six affected individuals. The X-axis the quantile of the statistic (i.e. 0.1. represents a study where we select the 10% of affected families with the
highest PRS statistic). In all four panels, the color indicates the PRS heritability (red, purple, blue indicates s2S ¼ 0:3, 0.1, and 0.05 respectively), the MAF is fixed at pG
= 0.0001, the polygenic heritability is fixed at s2P ¼ 0:3, and the disease prevalence is fixed at 100π
� = 2%. See Supporting Information: S4 Fig for other diseases with
other prevalences and HPRV MAFs.
https://doi.org/10.1371/journal.pgen.1008490.g004
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based on Ti) results in approximately 10–20% power to detect a HPRV. Moreover, when that
enrichment approaches 3x (e.g. s2S ¼ s
2
P ¼ 0:3 in affected sibships), the power using only the
enriched subset can exceed that using all subjects. We note that for other examples, especially
those where nearly all affected individuals carry the HPRV, selection by the PRS statistic can,
at best, only modestly improve power.
Finally, we evaluated the MelaNostrum families. In this study, there are 229 families from
Italy and 175 families from Spain with at least one melanoma case genotyped and sequenced.
The median number of individuals per family is 11 and the corresponding interquartile range
(IQR) is 6–19 individuals per family. The median number of cases per family is 3 with 34%
and 15% of families having at least 4 and 6 cases per family, respectively. The total number of
genotyped individuals is 990, the number of genotyped cases is 711, and the number of
sequenced cases is 606. We identified 29 families where at least one affected individual had a
rare potentially deleterious variant, as defined in the Methods, from ACD (3 families), BAP1
(2), CDKN2A (8), POT1 (11), TERF2IP (3), and TERT (2). We found that the mean family PRS
(i.e. the average PRS over all affected and genotyped relatives) in these 29 families was signifi-
cantly lower than the mean PRS in the 368 families without a known variant, 0.09 vs 0.55 (p-
value = 0.01 from t-test adjusted for country). However, we did not find the family structure or
disease pattern to be related to HPRV status. Even simple metrics, such as the number or pro-
portion of family members with disease, did not significantly differ by HPRV status. Therefore,
not surprisingly, the test statistic, Ti was similar in the two sets of families with the mean (Stan-
dard Error, SE) in families with and without an HPRV being 0.51 (0.05) and 0.44(0.02) respec-
tively. Finally, we note that in this example, the PRS provided only modest contributions to Ti
given the limited number of genotyped individuals in each family (Fig 5) and that the spear-
man correlation coefficient between the test statistics, Ti and T�i , that consider and do not con-
sider PRS was 0.92.
Discussion
Genetics is the primary cause of the familial aggregation of diseases. Either sharing a highly
penetrant rare variant (HPRV), risk alleles at multiple common variants, or a combination of
both can lead to numerous cases of a disease within a family. In this paper, we aimed to
describe the proportion of afflicted families likely to carry an HPRV, evaluate the ability for
polygenic risk scores (PRS) to identify those families carrying an HPRV, and to offer a test sta-
tistic for prioritizing families for sequencing studies.
The first message is that for diseases with a prevalence > 1%, a proportion of afflicted fami-
lies will not carry an HPRV. Unfortunately, as the number or penetrance of HPRVs for any
disease is unknown, we cannot yet predict the true proportion of afflicted families who will
carry HPRV. The purpose of this paper is only to show that, at least in some scenarios, there
may be a significant proportion of families who do not carry an HPRV. In the future, as we
continue to collect genetic information about afflicted families and new HPRVs, we might be
able to postulate which of the simulated scenarios most likely reflects truth. Currently, we are
limited to combining observed sibling relative risks, estimates of polygenic heritability, and
disease specific knowledge of genetics to determine the realistic boundaries of possible models.
We note that for rare diseases (e.g. disease prevalence 0.5%), our simulations suggest that it is
difficult to obtain significant familial enrichment (e.g. affected sibships with four siblings)
without the presence of an HPRV.
The second message is PRS can be used to identify those families most likely to be harbor-
ing an HPRV. Although this was expected, the surprising finding was that families with a low
average PRS tended to be significantly enriched for HPRV even when the heritability explained
Common Genetic Variants and Familial Aggregation
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by the PRS was relatively low (s2S ¼ 0:05), suggesting that current versions of PRS could be
potentially useful in selecting families for sequencing studies for non-rare diseases. This is
important, since the cost per sample of SNP genotyping is much lower than that for whole
exome sequencing. However, before promoting its usage, it would be important to show, in
multiple studies, that the PRS are lower in families carrying HPRV. MelaNostrum would be
one example, albeit with limited sample size, to suggest that families with an HPRV have lower
PRS, despite melanoma being a relatively rare disease in these Mediterranean populations (age
standardized incidence rate per 100,000 persons = 6.9 and 11.4 in Spain and Italy, respectively
[18]). However, the newly developed statistic, which in theory should be more strongly corre-
lated with the presence of an HPRV, did not differ across the two sets of families with and
without an HPRV. We expect that our statistic will perform better in future studies, but it is
worth considering why the statistic likely failed to differentiate families with and without an
HPRV in MelaNostrum. First, we note that our statistic combines two types of information,
the disease pattern in the family and the PRS. The first type, or disease pattern, is a time-tested
Fig 5. This figure compares the test statistic, Ti, that accounts for PRS and the test statistic, T�i , that does not account for
PRS in the 404 families with Melanoma. Each dot represents one family and red dots indicate families with an HPRV. The
spearmen correlation (ρ) between Ti and T�i is 0.92.
https://doi.org/10.1371/journal.pgen.1008490.g005
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means for identifying families carrying an HPRV; families with a large number of afflicted
individuals tend to carry HPRV. The second type, or PRS, is the comparatively novel informa-
tion used for identifying such families. However, in the MelaNostrum example, it is the disease
patterns that do not appear to have utility. One partial explanation is that, in this study, where
each family had only an average of three cases, the disease patterns might not have varied
enough as to be able to differentiate carriers of HPRV. Otherwise, we are left with conjectures,
such that families may have misreported disease incidence and there are many HPRV beyond
those in predefined genes. If a low mean PRS, as opposed to a high T, continues to be a better
predictor of the presence of an HPRV in future studies, the simpler statistic might be a better
way to select families. Note, the superiority of the PRS statistic might be possible, if not likely,
if identifying diseased individuals in extended families is prone to error.
We showed some extreme examples where simple case-control studies had higher statistical
power when only using the subset of cases with the highest values of Ti, as opposed to all cases.
In such scenarios, we could clearly gain power by using all cases if we modified the statistical
test. For example, we might compare the proportion of controls carrying an HPRV to a
weighted average of the genotypes in the affected family members, where the weights are lower
for individuals with higher PRS. As sequencing costs continue to decrease and studies no lon-
ger need to select a limited number of individuals, weighting will become a more valuable use
of PRS. Therefore, future investigations should evaluate the potential gains of weighting.
We are not the first to suggest using PRS to select individuals for sequencing studies and
specifically built our approach upon the elegant ideas proposed by Jostins [17]. We extend
prior ideas by introducing a new statistic that attempts to estimate the number of HPRVs,
accounting for ungenotyped individuals by modeling the PRS as a multivariate normal distri-
bution instead of imputing individual genotypes, and by considering the influence of the total
polygenic heritability. We expect the performance of both statistics, as well as the simpler aver-
age PRS in a family, to be evaluated with actual data as it becomes available.
We have pointed out two main limitations of our study. First, both our predictions about
the presence of an HPRV and the form of our test statistic rely on the liability threshold model.
Although this model has been a staple of genetics for over 80 years [19], the model has never
been evaluated for its accuracy in estimating the predictive capacity of polygenic risk scores.
Second, without knowledge of either the number or penetrance of these rare causal variants,
we cannot offer precise predictions about the true proportion of families carrying an HPRV or
the utility of PRS in selecting families for sequencing. Finally, it is worth highlighting a general
limitation of PRS. For most diseases, PRS were developed in European populations and their
predictive accuracy will be lower in other populations. Therefore, the benefits of our proposed
method for selecting afflicted families may be greatly diminished when the PRS was, in fact,
developed in a European population but the study’s families have non-European ancestry. The
performance of the method would be further comprised if the imputation quality of the
imputed SNPs used in the PRS was poor because the families’ ancestries were not properly
included on the imputation panel. Despite these limitations, we have proposed a new test sta-
tistic for identifying families with an HPRV and believe that the performance of the statistic
may be worth exploring in future studies.
Methods
We divide our Methods into four sections, describing the notation, the PRS-statistic, the sce-
narios for inquiry, and the WES study of Melanoma.
Common Genetic Variants and Familial Aggregation
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Notation
We assume that there is a single highly penetrant rare variant (HPRV), but note that our
framework holds for multiple HPRVs with appropriate modifications to the definitions (e.g.
“pG” would be the combined frequency of all HPRVs).
nF is the total number of families available for sequencing (i 2 {1,. . .nF} indexes families).
Ni is the number of individuals in family i (k 2 {1,. . .Ni} will index family members).
Oi� {1, . . . Ni} is the subset of diseased individuals to be sequenced.
Dik 2 {0,1} indicates the disease status; Di ¼ fDi1; . . . ;DiNig.
Gik 2 {0,1,2} indicates the genotype at the rare variant; Gi ¼ fGi1; . . . ;GiNig.
Sik is the Polygenic Risk Score (PRS); Si: ¼ fSi1; . . . ; SiNig.
pG is the Minor Allele Frequency (MAF) of the variant defining Gik.
s2S ¼ varðSikÞ is the polygenic risk score heritability.
π. = {π0,π1,π2} are the prevalences/penetrances of disease in individuals with Gik = 0, 1, and 2.
p� ¼ p0ð1   pGÞ
2
þ p12pGð1   pGÞ þ p2p2G is the overall prevalence of disease in the population.
s2P is the total polygenic heritability.
We are assuming that the liability threshold model, described in the next paragraph, is true
and that the underlying disease liability (Lik) can be decomposed into a polygenic effect from
identified sources (Sik), a polygenic effect from unidentified sources ðSUikÞ, and a non-genetic effect
(�ik) with Lik ¼ Sik þ SUik þ �ik and the polygenic heritability defined by s
2




The disease liability and its three components follow multivariate normal distributions. Letting
I be the Ni × Ni identity matrix and Si be the kinship matrix for family i,





















The disease thresholds (ci.) depend on Genotypes (Gi.) and population-level penetrances
(π0, π1,π2). In other words, the disease threshold for a given person depends on whether that
individual has a rare variant (i.e. in the presence of a rare variant, liability need not be as large
for the disease to occur). Letting F be the cumulative distribution for the standard normal dis-
tribution, define cg ¼ F
  1ð1   pgÞ and cik ¼ cGik . Then, the liability threshold model states that
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the disease status for an individual is determined by
Dik ¼
1 if Lik � cik
0 if Lik < cik
(
PRS statistic
We will define our PRS statistic so that families with a higher value are, by some measure,
more likely to carry a risk allele at the rare variant under investigation.
For defining the statistic, let Xi � XiðDi�;Gi�Þ ¼
P
k2Oi
Gik be the total number of rare alleles
among the ni sequenced cases in a family and Vi = var0(Xi) be the variance of Xi under the null
hypothesis, when the variant does not affect disease. Then, we define the PRS-statistic for the





and show how to calculate Ti in the Supporting Information: S1 Doc, with the assumptions
that the liability threshold model is true and all parameters are known. We show how to calcu-
late Ti when only a subset of individuals have PRS information in the Supporting Information:

















The first term on the right side is proportional to the expected number of HPRV per indi-
vidual. The second term is the adjustment that accounts for the correlation of the genotypes
among family members. In other words, we are not only interested in the average number of
HPRV per individual, but we are interested in subsequent test statistic that accounts for the
variance of that average.
Scenarios
We describe the metrics and scenarios that we use to evaluate the characteristics of familial
aggregation and study power. We estimate the metrics by simulating populations (and studies)
according to the liability threshold model. We start by identifying the pedigree of interest,
which is either the sibship or multi-generational family. Based on the genetic parameters (i.e.
MAF, s2S; s
2
p; pG), we then simulate > 50,000,000 pedigrees (i.e. Gi� Di� Li�, Si�). Finally, we iden-
tify at least 10,000 families with the specified disease pattern and calculate their test statistics.
From this group of families, we calculate all desired metrics.
We start by defining the three key metrics: Ep, β(qT) and M(qT). Our first objective is to esti-
mate the proportion, Ep, of individuals in afflicted families that have at least one rare-variant
Ep ¼ E½1ðGik > 0ÞjDik ¼ 1�
and show that Ep is not always close to 1. Our second objective is to estimate the power, β(qT),
of a hypothetical study that selects the qT × nF families with the highest values of Ti. Note, nF is
the total number of available families and, for our exposition, will be defined so that the study
Common Genetic Variants and Familial Aggregation
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power is 0.6 when qT = 1. This hypothetical study then sequences all diseased individuals from
the selected families, calculates an estimate, p̂GðqTÞ, of the MAF in those individuals, and tests






, where we assume
the overall MAF accounts for 1000 rare variants, p�G ¼ pG=1000 and p̂
�
G ¼ p̂G=1000. Then the
power is defined by
bðqTÞ ¼ PrðZðqTÞ > 5:32Þ
where the threshold is chosen to correspond to a p-value of 5 ×10-8. As part of this second
objective, we will also discuss the enrichment M(qT) of rare-variants in families at the top qthT
percentile of Ti among afflicted families
MðqTÞ ¼
E½1ðGik > 0ÞjDik ¼ 1;Ti ¼ F  1T ð1   qTÞ�
E½1ðGik > 0ÞjDik ¼ 1�
where FT is the distribution function of Ti.
We next define the scenarios for evaluating the three metrics. We consider two simple fam-










children having disease, with the grandchildren evenly split among the children. Note, we only
consider the individuals in the second and third generations (i.e. assume we cannot sequence














2 f3; 6; 9g. We simulate these families assuming s2P 2 f0:15; 0:30; 0:45g,
s2S 2 f0:1; 0:3g, pg 2 f0:00001; 0:0001; 0:001; 0:01g, and p
� 2 f0:005; 0:02; 0:05g. We
acknowledge that an allele with MAF = 0.01 would not be considered rare, but this MAF could
represent the combined frequency of 1000’s of rare variants. For all scenarios, π1 = 0.5, and π2
= 0.5.
MelaNostrum consortium
We considered melanoma-prone families participating in the MelaNostrum consortium. As
part of this consortium, 6961 affected individuals from Italy, Spain, and Greece and 5553 con-
trols were successfully genotyped using the Illumina OmniExpress Array. Moreover, a select
subcohort of cases from 404 melanoma-prone families successfully received Whole Exome
Sequencing (WES) or had been previously identified as carrying a CDKN2A mutation. Full
details of genotyping, sequencing, and family selection have been described elsewhere [20, 21]
and a brief summary is also provided in the Supporting Information: S1 Doc. For the PRS, we
used the SNPs previously identified in the MelaNostrum consortium [22]. Of the 204 identi-
fied SNPs, 193 were carried by the subgroup of cases from the melanoma-prone families. We
multiplied the genotype, coded as 0/1/2, by the beta coefficient for these SNPs and calculated
the PRS by subtracting off the mean of the country-specific controls and dividing by the stan-
dard deviation in those same controls. For reference, we approximated the PRS heritability of
melanoma in the Italy and Spain cohorts to be respectively 0.03 and 0.05 by performing linear
regression with disease status and PRS as the dependent and independent variables, obtaining
the coefficient b̂PRS and estimating s
2
S by 1   varðRiÞ=varðDiÞ where Ri ¼ Di   b̂PRSSi. We then
identified the potential Highly Penetrant Rare Variants (HPRV) in one of 7 genes (CDKN2A,
CDK4, BAP1, TERT, POT1, ACD, TERF2IP) previously associated with melanoma [23]. After
creating a list of all variants passing QC filters, we removed variants meeting any of the follow-
ing criteria: 1) Minor Allele Frequency (MAF) > 0.001 in ExAC Non-Finish Europeans,
Common Genetic Variants and Familial Aggregation
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MAF > 0.001 in both ExAC and the 1000 genome database, or MAF > 0.001 in our in-house
Eagle controls (same population). 2) Listed as low/modifier consequences mutations ("3’UTR",
"5’UTR", "3’Flank", "Targeted_Region", "Silent", "Intron", "RNA", "IGR", "Splice_Region",
"5’Flank", "lincRNA"). 3) In WES samples, a note of “CScoreFilter” under FILTER column in
VCF files or a genotype called as “0/0”. We note that 33 variants were missense mutations,
while the remaining three included two frameshift deletions (CDKN2A, ACD) and one non-
sense mutation (POT1).
Supporting information
S1 Doc. This word document contains an expanded methods sections detailing genotyping
and sequencing procedures, a discussion about the properties of the liability-threshold
model, and results from additional simulations.
(DOCX)
S1 Tab. This .txt file lists the SNPs and their coefficients used for calculating the polygenic
risk score.
(TXT)
S2 Tab. This .txt files lists the rare potentially deleterious variants identified in the Mela-
Nostrum families.
(TXT)
S1 Fig. The relative risk of disease as a function of the PRS score. Note that the liability
threshold model has interesting implications for polygenic risk scores (PRS). In brief, individ-
uals in the population with a low PRS have an extremely low risk of disease. If the disease has a
prevalence of 0.01, then the relative risk of disease (e.g. probability of disease divided by 0.01)
in individuals at the bottom 10th percentile are approximately 0.01, 0.2, and 0.4 for PRS herita-
bilities of 0.05, 0.1, and 0.3. Moreover, the total heritability is irrelevant to these calculations.
These results emphasize that even when the polygenic risk scores account for minimal herita-
bility, individuals in the lowest percentiles are at a greatly reduced risk of disease.
(TIF)
S2 Fig. Proportion carrying HPRV in affected sibships. The proportion (Ep) of individuals
carrying a highly penetrant rare variant (HPRV) in affected sibships for a disease with a 0.5%,
2% or 5% prevalence (100 × π�) in the population. Columns represent different values of poly-
genic heritability and rows represent different prevalences. Within a panel, the four sets of bars
represent different MAF (pG = 0.00001, 0.0001, 0.001, or 0.01; note, the number in parenthesis
is the resulting Sibling Relative Risk). Within a set of bars, the colors represent different the














S3 Fig. Proportion carrying HPRV in multi-generational families. The proportion (Ep) of
individuals carrying a highly penetrant rare variant (HPRV) in affected multi-generational
families for a disease with a 0.5%, 2%, or 5% prevalence (100 × π�) in the population. Columns
represent different values of polygenic heritability and rows represent different prevalences.
Within a panel, the four sets of bars represent different MAF (pG = 0.00001, 0.0001, 0.001, or
0.01; note, the number in parenthesis is the resulting Sibling Relative Risk). Within a set of
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S4 Fig. Enrichment and power to detect HPRV by the PRS statistic. The first two columns
show the enrichment (M) of HPRV as a function of the PRS statistic when a sibship has four
affected individuals and when a multi-generational family has six affected individuals. The
X-axis is the quantile of the statistic (i.e. 0.1 represents a family at the top 10th percentile). The
last two columns show the power (β) to detect an association with the HPRV when a sibship
has four affected individuals and when a multi-generational family has six affected individuals.
The X-axis the quantile of the statistic (i.e. 0.1. represents a study where we select the 10% of
affected families with the highest PRS statistic). In all four panels, the color indicates the PRS
heritability (red, purple, blue indicates s2S = 0.3, 0.1, and 0.05 respectively) and the polygenic
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Aguilera, Llúcia Alós, Celia Badenas, Alicia Barreiro, Neus Calbet, Cristina Carrera, Carlos
Conill, Mireia Domı́nguez, Daniel Gabriel, Pablo Iglesias, Josep Malvehy, M. Eugenia Moliner,
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